Resources

AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.

To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database

Results

showing 1-10 of 282

Years Ahead in HIV Prevention Research: Time to Market

This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.

May 2024


New Product Introduction Update

A graphic showing ongoing studies of injectable cabotegravir and the dapivirine vaginal ring in eastern and southern Africa.

May 2024


An Overview of Lenacapavir for PrEP Trials

The PURPOSE efficacy trials are expected to report results later this year or in early 2025. If the six-monthly injectable lenacapavir demonstrates safety and efficacy, it will be the next long-acting injectable PrEP option to enter the market—and it is not too early to plan.

Prevention Option:

May 2024


Moving a Product to the Real World

To reach the UNAIDS target of 10 million PrEP users by 2025, initiations of oral PrEP alone will not be enough—and this graphic shows that the field is beginning to apply past lessons to accelerate introduction of injectable cabotegravir.

Prevention Option:

May 2024


Oral PrEP in Cisgender Women

Displayed in these two graphics: researchers documented patterns of adherence for oral PrEP and we graphed HIV incidence based on weekly F/TDF adherence in cisgender women.

Prevention Option:

May 2024


Top Vaccines Funders

Total US dollars invested by each of the top 10 global funders of vaccine research in 2022.

May 2024


PrEP Initiations by Country Worldwide

AVAC tracks global PrEP use by conducting quarterly surveys of ongoing oral PrEP demonstration and implementation projects, and collecting data from manufacturers and government agencies. This graphic shows data on PrEP initiations around the globe.

Prevention Option:

May 2024


The Years Ahead in Biomedical HIV Prevention Research

This graphic shows the updated status of large-scale prevention trials through the end of 2024.

May 2024


HIV Vaccine and Antibody Efficacy Trials to Date

This infographic provides a comprehensive overview of HIV vaccine and antibody efficacy trials. Over 20 years and 12 trials, only two positive signals have been observed.

April 2024


Allocation of Non-Commercial CAB for PrEP Supply in Low- and Middle-Income Countries, 2023-2025

Malaysia, Nigeria, Peru, Zambia, and the European Medicines Agency have approved CAB for PrEP; ViiV also made submissions in Canada, Colombia, and the United Kingdom. There are now 13 regulatory approvals and 15 additional submissions that are pending.

Prevention Option:

April 2024


showing 1-10 of 282